ES2685374T3 - Nueva composición para la reducción extracorpórea de beta amiloides y procedimiento de producción de la misma - Google Patents
Nueva composición para la reducción extracorpórea de beta amiloides y procedimiento de producción de la misma Download PDFInfo
- Publication number
- ES2685374T3 ES2685374T3 ES13781268.1T ES13781268T ES2685374T3 ES 2685374 T3 ES2685374 T3 ES 2685374T3 ES 13781268 T ES13781268 T ES 13781268T ES 2685374 T3 ES2685374 T3 ES 2685374T3
- Authority
- ES
- Spain
- Prior art keywords
- blood
- capture
- binding agent
- beta amyloid
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title claims abstract description 84
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 58
- 230000009467 reduction Effects 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 2
- 210000004369 blood Anatomy 0.000 claims abstract description 106
- 239000008280 blood Substances 0.000 claims abstract description 106
- 239000011230 binding agent Substances 0.000 claims abstract description 62
- 238000001914 filtration Methods 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 239000000385 dialysis solution Substances 0.000 claims abstract description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 25
- 108010075875 amyloid beta-protein (16-20) Proteins 0.000 claims abstract description 24
- 230000001575 pathological effect Effects 0.000 claims abstract description 22
- 239000000243 solution Substances 0.000 claims abstract description 21
- 238000009472 formulation Methods 0.000 claims abstract description 9
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 230000002441 reversible effect Effects 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 5
- 239000012528 membrane Substances 0.000 claims description 71
- 208000024827 Alzheimer disease Diseases 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 230000027455 binding Effects 0.000 claims description 12
- 231100000189 neurotoxic Toxicity 0.000 claims description 12
- 230000002887 neurotoxic effect Effects 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 239000011148 porous material Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 11
- 239000003053 toxin Substances 0.000 claims description 11
- 231100000765 toxin Toxicity 0.000 claims description 11
- 108700012359 toxins Proteins 0.000 claims description 11
- 238000009739 binding Methods 0.000 claims description 10
- 239000000470 constituent Substances 0.000 claims description 10
- 238000001631 haemodialysis Methods 0.000 claims description 9
- 230000000322 hemodialysis Effects 0.000 claims description 9
- 230000001413 cellular effect Effects 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 208000002177 Cataract Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000000178 monomer Substances 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- JYYOBHFYCIDXHH-UHFFFAOYSA-N carbonic acid;hydrate Chemical compound O.OC(O)=O JYYOBHFYCIDXHH-UHFFFAOYSA-N 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 description 53
- 210000002381 plasma Anatomy 0.000 description 44
- 206010002022 amyloidosis Diseases 0.000 description 30
- 239000000306 component Substances 0.000 description 20
- 239000012530 fluid Substances 0.000 description 15
- 239000000499 gel Substances 0.000 description 15
- 230000001105 regulatory effect Effects 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 239000007767 bonding agent Substances 0.000 description 8
- 230000004087 circulation Effects 0.000 description 8
- 238000001179 sorption measurement Methods 0.000 description 8
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical group C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 6
- 108010088751 Albumins Proteins 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 241000601295 Bairdiella ronchus Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
- FEWOUVRMGWFWIH-ILZZQXMPSA-N amyloid-beta polypeptide 40 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 FEWOUVRMGWFWIH-ILZZQXMPSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 102100034004 Gamma-adducin Human genes 0.000 description 2
- 101000799011 Homo sapiens Gamma-adducin Proteins 0.000 description 2
- 241000607479 Yersinia pestis Species 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 210000003567 ascitic fluid Anatomy 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000006911 nucleation Effects 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- PTJWCLYPVFJWMP-UHFFFAOYSA-N 2-[[3-hydroxy-2-[[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propoxy]methyl]-2-(hydroxymethyl)propane-1,3-diol Chemical group OCC(CO)(CO)COCC(CO)(CO)COCC(CO)(CO)CO PTJWCLYPVFJWMP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010001526 Air embolism Diseases 0.000 description 1
- 102000001049 Amyloid Human genes 0.000 description 1
- 108010094108 Amyloid Proteins 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108090000197 Clusterin Proteins 0.000 description 1
- 102000003780 Clusterin Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010071690 Prealbumin Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108010045517 Serum Amyloid P-Component Proteins 0.000 description 1
- 102100036202 Serum amyloid P-component Human genes 0.000 description 1
- 102000009190 Transthyretin Human genes 0.000 description 1
- 108010065472 Vimentin Proteins 0.000 description 1
- 102000013127 Vimentin Human genes 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 102100035140 Vitronectin Human genes 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003541 chymotrypsin inhibitor Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 125000003827 glycol group Chemical group 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000005048 vimentin Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
- A61M1/1654—Dialysates therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2207/00—Methods of manufacture, assembly or production
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- External Artificial Organs (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261638672P | 2012-04-26 | 2012-04-26 | |
| US201261638672P | 2012-04-26 | ||
| PCT/PH2013/000005 WO2013162387A1 (en) | 2012-04-26 | 2013-01-30 | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof |
| PH1/2013/000037A PH12013000037A1 (en) | 2013-01-30 | 2013-01-30 | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2685374T3 true ES2685374T3 (es) | 2018-10-08 |
Family
ID=49483563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13781268.1T Active ES2685374T3 (es) | 2012-04-26 | 2013-01-30 | Nueva composición para la reducción extracorpórea de beta amiloides y procedimiento de producción de la misma |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20150087591A1 (enExample) |
| EP (1) | EP2841447B1 (enExample) |
| JP (1) | JP2015515491A (enExample) |
| KR (2) | KR20180117226A (enExample) |
| CN (2) | CN104662032A (enExample) |
| AU (2) | AU2013253098A1 (enExample) |
| CA (1) | CA2871585A1 (enExample) |
| DK (1) | DK2841447T3 (enExample) |
| ES (1) | ES2685374T3 (enExample) |
| HR (1) | HRP20181365T1 (enExample) |
| IN (1) | IN2014MN02137A (enExample) |
| LT (1) | LT2841447T (enExample) |
| PH (1) | PH12013000037A1 (enExample) |
| PL (1) | PL2841447T3 (enExample) |
| RS (1) | RS57651B1 (enExample) |
| SG (1) | SG11201406972UA (enExample) |
| SI (1) | SI2841447T1 (enExample) |
| SM (1) | SMT201800445T1 (enExample) |
| WO (1) | WO2013162387A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106800590B (zh) * | 2015-11-25 | 2021-04-09 | 杭州智鹤丹谷生物医药有限公司 | 一种结合多种淀粉样蛋白单体和聚集体的多肽及其应用 |
| CN105651840B (zh) * | 2016-04-01 | 2017-12-26 | 商丘师范学院 | 一种检测β‑淀粉样蛋白寡聚体的类免疫电化学传感器及其制备方法 |
| CN109954128A (zh) * | 2019-03-08 | 2019-07-02 | 南开大学 | 一种可干扰β-淀粉样蛋白聚集并协助清除的功能化纳米凝胶及制备方法 |
| CN114933635B (zh) * | 2021-08-29 | 2023-05-19 | 武汉夫图生物科技有限公司 | 纳米小肽fh及其在制备治疗及预防眼底血管疾病药物中的应用 |
| CA3239637A1 (en) * | 2021-12-23 | 2023-06-29 | Fresenius Medical Care Holdings, Inc. | Compounds, systems, and techniques for removal of peripheral amyloid beta peptide with albumin binding competitors |
| CN115337388A (zh) * | 2022-07-01 | 2022-11-15 | 南方医科大学 | 一种抗菌和预防hpv病毒的按需释放凝胶及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5223199B2 (enExample) * | 1972-05-27 | 1977-06-22 | ||
| JPS4942189A (enExample) * | 1972-08-29 | 1974-04-20 | ||
| CA2214247C (en) * | 1995-03-14 | 2004-02-10 | Praecis Pharmaceuticals Incorporated | Modulators of amyloid aggregation |
| JPH09157283A (ja) * | 1995-12-13 | 1997-06-17 | Tatsuaki Yamaguchi | 燐酸吸着コロイド |
| US6022859A (en) * | 1996-11-15 | 2000-02-08 | Wisconsin Alumni Research Foundation | Inhibitors of β-amyloid toxicity |
| AU2003303198A1 (en) * | 2002-12-19 | 2004-07-14 | New York University | Method for treating amyloid disease |
| US20060069010A1 (en) * | 2003-10-17 | 2006-03-30 | Senicure Llc | Detoxification depot for Alzheimer's disease |
| US20070092508A1 (en) * | 2005-10-21 | 2007-04-26 | Recombiant Technologies, Llc | Detoxification depot for Alzheimer's disease |
| CA2780645C (en) * | 2009-11-18 | 2018-01-16 | Nektar Therapeutics | Salt form of a multi-arm polymer-drug conjugate |
| CN102108119A (zh) * | 2009-12-25 | 2011-06-29 | 天津键凯科技有限公司 | 多臂聚乙二醇衍生物及其与药物的结合物和凝胶 |
| JP5843345B2 (ja) * | 2010-07-08 | 2016-01-13 | 旭化成メディカル株式会社 | β−アミロイド除去システム |
-
2013
- 2013-01-30 WO PCT/PH2013/000005 patent/WO2013162387A1/en not_active Ceased
- 2013-01-30 EP EP13781268.1A patent/EP2841447B1/en active Active
- 2013-01-30 AU AU2013253098A patent/AU2013253098A1/en not_active Abandoned
- 2013-01-30 SM SM20180445T patent/SMT201800445T1/it unknown
- 2013-01-30 US US14/397,486 patent/US20150087591A1/en not_active Abandoned
- 2013-01-30 LT LTEP13781268.1T patent/LT2841447T/lt unknown
- 2013-01-30 JP JP2015508893A patent/JP2015515491A/ja active Pending
- 2013-01-30 SI SI201331147T patent/SI2841447T1/sl unknown
- 2013-01-30 PH PH1/2013/000037A patent/PH12013000037A1/en unknown
- 2013-01-30 ES ES13781268.1T patent/ES2685374T3/es active Active
- 2013-01-30 DK DK13781268.1T patent/DK2841447T3/en active
- 2013-01-30 KR KR1020187030342A patent/KR20180117226A/ko not_active Ceased
- 2013-01-30 CN CN201380027665.5A patent/CN104662032A/zh active Pending
- 2013-01-30 CN CN201811292445.6A patent/CN109731169A/zh active Pending
- 2013-01-30 PL PL13781268T patent/PL2841447T3/pl unknown
- 2013-01-30 RS RS20181008A patent/RS57651B1/sr unknown
- 2013-01-30 HR HRP20181365TT patent/HRP20181365T1/hr unknown
- 2013-01-30 KR KR20147030161A patent/KR20150022753A/ko not_active Ceased
- 2013-01-30 IN IN2137MUN2014 patent/IN2014MN02137A/en unknown
- 2013-01-30 CA CA2871585A patent/CA2871585A1/en active Pending
- 2013-01-30 SG SG11201406972UA patent/SG11201406972UA/en unknown
-
2016
- 2016-07-25 AU AU2016208257A patent/AU2016208257B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP2841447B1 (en) | 2018-06-13 |
| RS57651B1 (sr) | 2018-11-30 |
| PH12013000037A1 (en) | 2013-10-14 |
| KR20180117226A (ko) | 2018-10-26 |
| US20150087591A1 (en) | 2015-03-26 |
| AU2016208257B2 (en) | 2018-08-16 |
| DK2841447T3 (en) | 2018-09-03 |
| EP2841447A4 (en) | 2015-10-28 |
| PL2841447T3 (pl) | 2019-03-29 |
| JP2015515491A (ja) | 2015-05-28 |
| CN104662032A (zh) | 2015-05-27 |
| AU2016208257A1 (en) | 2016-08-11 |
| IN2014MN02137A (enExample) | 2015-08-21 |
| HRP20181365T1 (hr) | 2018-10-19 |
| AU2013253098A2 (en) | 2015-04-30 |
| WO2013162387A1 (en) | 2013-10-31 |
| SI2841447T1 (sl) | 2018-10-30 |
| CN109731169A (zh) | 2019-05-10 |
| LT2841447T (lt) | 2018-09-10 |
| EP2841447A1 (en) | 2015-03-04 |
| AU2013253098A1 (en) | 2014-11-13 |
| SMT201800445T1 (it) | 2018-09-13 |
| SG11201406972UA (en) | 2014-11-27 |
| KR20150022753A (ko) | 2015-03-04 |
| CA2871585A1 (en) | 2013-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2016208257B2 (en) | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof | |
| US20070181499A1 (en) | Plasma detoxification and volume control system and methods of use | |
| ES2628513T3 (es) | Un filtro de perfusión sanguínea de inmunoactivación para el tratamiento de tumores malignos | |
| ES2676593T3 (es) | Aparato de perfusión extracorpórea | |
| JP2000107286A (ja) | 腹膜透析液の灌流装置及び灌流法 | |
| KR20150097785A (ko) | 혈액투석여과법 | |
| Reetze-Bonorden et al. | Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations | |
| WO2015095553A1 (en) | Methods and apparatus for kidney dialysis | |
| ES2348189T3 (es) | Kit para el tratamiento de enfermedades relacionadas con inflamacion sistematica. | |
| CN108752468A (zh) | 伤口喷剂 | |
| US5261876A (en) | Enhanced peritoneal membrane plasmapheresis | |
| Kawaguchi et al. | Toward the treatment for Alzheimer’s disease: adsorption is primary mechanism of removing amyloid β protein with hollow-fiber dialyzers of the suitable materials, polysulfone and polymethyl methacrylate | |
| JP3980588B2 (ja) | 血漿交換廃液浄化循環透析装置 | |
| AU2014101449A6 (en) | Novel composition for extracorporeal reduction of beta-amyloids and process for producing thereof | |
| US20100012588A1 (en) | system and method for the extra-corporeal purification of blood of pathogenic enzymes | |
| JP2020036881A (ja) | 透析装置、アクセプター薬剤、ドナー薬剤、リンス液およびリンス液としての使用方法 | |
| ES2382186T3 (es) | Aparato de diálisis con un sistema de regeneración | |
| Cantaluppi et al. | Blood purification for sepsis | |
| JP4947693B2 (ja) | アルブミンとアルブミンに結合した生体分子の分離方法 | |
| JP2007144228A (ja) | 血漿交換廃液浄化循環透析方法 | |
| JP6337175B2 (ja) | 急性又は慢性腎不全患者の血液からタンパク質結合毒素を除去するための透析法に使用される医薬組成物。 | |
| RU2269363C1 (ru) | Способ лечения печеночной недостаточности | |
| RU2264826C1 (ru) | Способ получения антитимоцитарного глобулина для внутривенного введения | |
| Cocchi et al. | Transport phenomena in dialysis processes | |
| ES2277169T3 (es) | Absorbedor de fibrinogeno iii. |